Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Lung Cancer

  Free Subscription


2 Ann Oncol
2 Anticancer Res
1 Arch Pathol Lab Med
3 BMC Cancer
3 Cancer
1 Cancer Cell
2 Cancer Lett
1 Cancer Sci
1 Clin Exp Metastasis
8 Clin Lung Cancer
4 Eur J Cardiothorac Surg
2 Int J Radiat Oncol Biol Phys
4 J Clin Oncol
2 Lung Cancer
1 Mol Carcinog
2 Oncogene
1 Oncologist
3 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Oncol

  1. PASSARO A, Wang J, Shah S, Bauml JM, et al
    Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl
    Ann Oncol. 2024;35:328-329.

  2. MOIK F, Riedl JM, Ay C
    Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
    Ann Oncol. 2024;35:327.

    Anticancer Res

  3. INOMATA M, Minatoyama S, Takata N, Hayashi K, et al
    Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy.
    Anticancer Res. 2024;44:1241-1245.
    PubMed         Abstract available

  4. KINOSHITA H, Kinoshita S, Kamoda H, Hagiwara Y, et al
    Combined Auranofin and Celecoxib Suppresses the Local Progression and Pulmonary Metastases of Osteosarcoma In Vivo.
    Anticancer Res. 2024;44:1045-1049.
    PubMed         Abstract available

    Arch Pathol Lab Med

  5. BLATNIK A, Dragos VS, Blatnik O, Stegel V, et al
    A Population-Based Study of Patients With Small Cell Carcinoma of the Ovary, Hypercalcemic Type, Encompassing a 30-Year Period.
    Arch Pathol Lab Med. 2024;148:299-309.
    PubMed         Abstract available

    BMC Cancer

  6. CHEN K, Li S, Chen M, Jin Z, et al
    Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy.
    BMC Cancer. 2024;24:257.
    PubMed         Abstract available

  7. WANG X, Zhao J, Mei T, Liu W, et al
    Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients.
    BMC Cancer. 2024;24:269.
    PubMed         Abstract available

  8. XU M, Li C, Xiang L, Chen S, et al
    Assessing the causal relationship between 731 immunophenotypes and the risk of lung cancer: a bidirectional mendelian randomization study.
    BMC Cancer. 2024;24:270.
    PubMed         Abstract available


  9. TAN AC, Lai GGY, Saw SPL, Chua KLM, et al
    Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35263.
    PubMed         Abstract available

    The expanding role of circulating tumor DNA in resectable non-small cell lung cancer.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35268.

  11. Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study".
    Cancer. 2024 Feb 23. doi: 10.1002/cncr.35165.

    Cancer Cell

  12. TONG X, Patel AS, Kim E, Li H, et al
    Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
    Cancer Cell. 2024 Feb 20:S1535-6108(24)00036-9. doi: 10.1016/j.ccell.2024.
    PubMed         Abstract available

    Cancer Lett

  13. HAN R, Lin C, Lu C, Wang Y, et al
    Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.
    Cancer Lett. 2024;588:216762.
    PubMed         Abstract available

  14. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
    Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Cancer Lett. 2024;584:216608.
    PubMed         Abstract available

    Cancer Sci

  15. KAJIWARA N, Kakihana M, Maeda J, Kaneko M, et al
    Salivary metabolomic biomarkers for non-invasive lung cancer detection.
    Cancer Sci. 2024 Feb 28. doi: 10.1111/cas.16112.
    PubMed         Abstract available

    Clin Exp Metastasis

  16. WIEGMANS AP, Ivanova E, Naei VY, Monkman J, et al
    Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer.
    Clin Exp Metastasis. 2024 Feb 28. doi: 10.1007/s10585-024-10270.
    PubMed         Abstract available

    Clin Lung Cancer

  17. BORGHETTI P, Facheris G, Ciammella P, Galaverni M, et al
    Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort.
    Clin Lung Cancer. 2024;25:151-158.
    PubMed         Abstract available

  18. GONZALEZ-MOSQUERA LF, Rous FA, Rogers A, Smith N, et al
    ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
    Clin Lung Cancer. 2024;25:e77-e80.
    PubMed         Abstract available

  19. VERMA S, Young S, Kennedy TAC, Carvalhana I, et al
    Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors (SABR-DETECT).
    Clin Lung Cancer. 2024;25:e87-e91.
    PubMed         Abstract available

  20. JENNINGS EM, Camidge DR, Gadgeel S, Barker S, et al
    Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC.
    Clin Lung Cancer. 2024;25:91-99.
    PubMed         Abstract available

  21. INNO A, Picece V, Bogina G, Settanni G, et al
    Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report.
    Clin Lung Cancer. 2024;25:175-179.

  22. ARDESHIR-LARIJANI F, Maniar R, Goyal S, Loehrer PJ, et al
    Trop-2 Expression and Its Impact on Survival in Thymic Epithelial Tumors: Brief Report.
    Clin Lung Cancer. 2024;25:180-185.

  23. WALIANY S, Neal JW, Engel-Nitz N, Lam C, et al
    HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.
    Clin Lung Cancer. 2024 Jan 18:S1525-7304(24)00004.
    PubMed         Abstract available

  24. WU Y, Zhao Y, Wu Y, Chen H, et al
    A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal Metastasis.
    Clin Lung Cancer. 2024 Feb 8:S1525-7304(24)00012.
    PubMed         Abstract available

    Eur J Cardiothorac Surg

  25. WANG RR, Li MJ, Peng Q, Huang ZY, et al
    Validation of the ninth edition of the TNM staging system for Non-Small cell lung cancer with lobectomy in stage IA-IIIA.
    Eur J Cardiothorac Surg. 2024 Feb 29:ezae071. doi: 10.1093.
    PubMed         Abstract available

  26. BARCELOS RR, Sugarbaker E, Kennedy KF, McAllister M, et al
    Time between imaging and surgery is not a risk factor for upstaging of clinical stage IA non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2024;65:ezae057.
    PubMed         Abstract available

  27. GONZALEZ M, Ojanguren A, Figueroa S, Bedat B, et al
    Segmentectomy for lung cancer: Dig deeper.
    Eur J Cardiothorac Surg. 2024 Feb 24:ezae066. doi: 10.1093.

  28. BERNARDI E, Diotti C, Bertolaccini L, Donghi S, et al
    Mediastinal cellulose pack mimicking lung cancer relapsing after lobectomy.
    Eur J Cardiothorac Surg. 2024 Feb 23:ezae065. doi: 10.1093.

    Int J Radiat Oncol Biol Phys

  29. LUCIA F, Bourhis D, Pinot F, Hamya M, et al
    Prediction of Acute Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy Using Dose-Volume Parameters From Functional Mapping on Gallium 68 Perfusion Positron Emission Tomography/Computed Tomography.
    Int J Radiat Oncol Biol Phys. 2024;118:952-962.
    PubMed         Abstract available

  30. FAROOQI AS, Yoder AK, Lin HY, Pasalic D, et al
    SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection.
    Int J Radiat Oncol Biol Phys. 2024;118:971-978.
    PubMed         Abstract available

    J Clin Oncol

  31. HENICK BS, Herzberg BO, Concepcion-Crisol CP, Taylor AM, et al
    Controlled Chaos: Parsing Acquired Immunoresistance in Lung Cancer.
    J Clin Oncol. 2024 Feb 29:JCO2302339. doi: 10.1200/JCO.23.02339.

  32. JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
    J Clin Oncol. 2024 Feb 28:JCO2302746. doi: 10.1200/JCO.23.02746.
    PubMed         Abstract available

  33. JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
    J Clin Oncol. 2024 Feb 28:JCO2302744. doi: 10.1200/JCO.23.02744.
    PubMed         Abstract available

  34. PIPER VALLILLO AJ, Viray H, Feldman J, Rangachari D, et al
    Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.
    J Clin Oncol. 2024 Feb 27:JCO2302417. doi: 10.1200/JCO.23.02417.
    PubMed         Abstract available

    Lung Cancer

  35. LEE JD, Zheng R, Okusanya OT, Evans NR 3rd, et al
    Association between surgical quality and long-term survival in lung cancer.
    Lung Cancer. 2024;190:107511.
    PubMed         Abstract available

  36. BAR J, Esteban E, Rodriguez-Abreu D, Aix SP, et al
    Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
    Lung Cancer. 2024;190:107506.
    PubMed         Abstract available

    Mol Carcinog

  37. FURUSAWA T, Cavero R, Liu Y, Li H, et al
    Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer.
    Mol Carcinog. 2024 Feb 27. doi: 10.1002/mc.23705.
    PubMed         Abstract available


  38. TURKOWSKI K, Herzberg F, Gunther S, Weigert A, et al
    miR-147b mediated suppression of DUSP8 promotes lung cancer progression.
    Oncogene. 2024 Feb 23. doi: 10.1038/s41388-024-02969.
    PubMed         Abstract available

  39. GAROFALO M, Quintavalle C, Di Leva G, Zanca C, et al
    Editorial Expression of Concern: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.
    Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02989.


  40. STRICKER T, Jain N, Ma E, Yu E, et al
    Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
    Oncologist. 2024 Feb 28:oyae022. doi: 10.1093.
    PubMed         Abstract available

    PLoS One

  41. MORI S, Ueki Y, Hasegawa M, Nakamura K, et al
    Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study.
    PLoS One. 2024;19:e0298573.
    PubMed         Abstract available

  42. WANG H, Tang H, Yuan S, Liang C, et al
    IL-17A deficiency inhibits lung cancer-induced osteoclastogenesis by promoting apoptosis of osteoclast precursor cells.
    PLoS One. 2024;19:e0299028.
    PubMed         Abstract available

  43. YOO SJ, Park YS, Choi H, Kim DS, et al
    Prospective evaluation of deep learning image reconstruction for Lung-RADS and automatic nodule volumetry on ultralow-dose chest CT.
    PLoS One. 2024;19:e0297390.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.